{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"SEGYOKHGGFKMCX-UHFFFAOYSA-N","prefName":"JZL184","symbol":"JZL184","iupacName":null,"aliases":["JZL-184"],"cas":"1101854-58-3","pubchemCid":"25021165","chebiId":null,"smiles":"C1CN(CCC1C(C2=CC3=C(C=C2)OCO3)(C4=CC5=C(C=C4)OCO5)O)C(=O)OC6=CC=C(C=C6)[N+](=O)[O-]","molecularFormula":"C27H24N2O9","molecularWeight":520.5,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/25021165"}},"classification":{"family":"ecs_tool","familyLabel":"Modulador del ECS (investigación)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origen (herramienta de investigación)","summaryFr":"Inhibidor covalente selectivo de la MAGL; obtenido por síntesis orgánica (carbamilación del residuo Ser122 catalítico)","originNote":"Investigación farmacéutica (Cravatt)","discovered":"2009"},"pharmacology":{"summaryFr":"JZL184 es el inhibidor de MAGL de referencia - descrito por Long, Li y Cravatt (Nat Chem Biol 2009, PMID 19029916) en el Scripps Research Institute. Mecanismo covalente irreversible (Ser122). La elevación crónica del 2-AG cerebral conduce a una desensibilización CB1 (down-regulation) que complica el uso crónico: la estrategia clínica privilegia hoy los inhibidores MAGL reversibles (ABX-1431 / lu AG06466) o más selectivos (MJN110, KML29).","receptorSummaryFr":"Inhibidor MAGL (IC50 ≈ 8 nM hMAGL) - eleva el 2-AG cerebral en un factor ≈ 10× sin afectar significativamente a la FAAH","binding":[{"target":"MAGL","efficacy":"antagonist","relativeActivity":95,"reported":"IC50 ≈ 8 nM (hMAGL)","confidence":"medium"},{"target":"CB1","efficacy":"modulator","relativeActivity":10,"reported":"indirect via 2-AG","confidence":"medium"}],"references":[{"label":"Long · Nat Chem Biol 2009","pmid":"19029916","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/19029916/"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calma","description":"Relajación del cuerpo y de la mente; menos ruido mental, sin somnolencia marcada.","intensity":70},{"key":"focus","label":"Claridad","description":"Atención sostenida y pensamiento claro; lucidez funcional, sin euforia.","intensity":50},{"key":"sleep","label":"Sueño","description":"Efecto sedante: favorece la conciliación del sueño y la continuidad del sueño profundo.","intensity":55},{"key":"appetite","label":"Apetito","description":"Estimulación del hambre y de la apreciación gustativa (efecto «munchies»).","intensity":60},{"key":"uplift","label":"High","description":"Euforia e intensidad sensorial; percepción del tiempo y del espacio modificada.","intensity":55}],"doseRanges":null,"humanDataCharacterised":true},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":false,"bannerTextFr":null,"toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"No listado","frScheduleStatus":null,"tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No listada","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"Herramienta de investigación, no listada","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Long · Nat Chem Biol 2009","pmid":"19029916","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/19029916/"}],"meta":{"slug":"jzl184","url":"https://es.phytogrammes.com/wiki/jzl184","lastVerified":"2026-05-01","dataUpdatedAt":"2026-05-01","confidence":"medium","dataCompletenessPct":80,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}